Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Assist. Prof. Dr. Mohamed skiba, University of rouen, France

Dr. Mohamed Skiba, is a French national and a distinguished pharmaceutical scientist. He is a lecturer at the Faculty of Medicine and Pharmacy in Rouen, where he leads the Pharmaceutical Team within the Galenic Group. Dr. Skiba earned his Ph.D. in Pharmaceutical Sciences from the University of Paris XI in 1994 and has been active in pharmaceutical research since 1990, focusing on cyclodextrin and drug vectorization. With over 140 international publications, 80 patents, and numerous contributions to books and congresses, he is a recognized expert in pharmaceutical technology. Dr. Skiba is also an active member of several scientific societies, including the French Society of Chemistry and the French Association of Teachers of Technological Pharmacy. He is fluent in French, English, and Arabic.

Professional Profile:

Orcid

Suitability for Best Innovation Award: Dr. Mohamed SKIBA

Dr. Mohamed Skiba’s extensive work in pharmaceutical sciences, particularly his research in drug formulation and cyclodextrin technologies, positions him as a strong candidate for the Best Innovation Award. His innovations, reflected in his numerous patents and publications, highlight his ability to drive pharmaceutical advancements with real-world applications. His leadership in academic and research institutions further amplifies his impact, making him a deserving recipient of this prestigious award.

🎓Education:

Dr. Mohamed Skiba holds a Ph.D. in Pharmaceutical Sciences, which he earned in 1994 from the University of Paris XI, Southern Paris. His academic journey also includes a Diploma of Thorough Studies in Pharmacotechnology and Biopharmacy (1990) from the University of Paris XI in Châtenay-Malabry. In 1990, he obtained a Diploma in Veterinary Pharmaceuticals from the Faculty of Pharmacy, University of Clermont-Ferrand I. Additionally, Dr. Skiba completed advanced studies in pharmacology and electrophysiology with a Control of Research degree from the University of Poitiers in 1989. He also pursued studies in patent rights at the Faculty of Orsay, University of Paris-South, enriching his expertise in pharmaceutical and intellectual property matters.

🏢Work Experience:

Dr. Mohamed Skiba has been a lecturer at the Faculty of Medicine and Pharmacy, University of Rouen, France, since 1998. In this role, he teaches courses in galenic and industrial galenic pharmacy to both undergraduate and graduate students, while also leading the Pharmaceutical Team within the Galenic Group. His professional experience includes serving as a trainee at the Central Pharmacy of the Hospitals of Paris (PCH) and working as an Associated Attaché in Toxicology and Clinical Pharmacology at the Hospital of Corbeil-Essonnes, further enhancing his expertise in pharmaceutical technology and clinical applications.

🏅Awards & Recognition:

Dr. Mohamed Skiba is a prolific contributor to the field of pharmaceutical technology, holding over 80 patents that highlight his innovative work. He has authored 140 international publications and contributed to 9 book chapters, making significant scholarly impacts. Additionally, Dr. Skiba has presented 71 communications at prestigious scientific congresses, sharing his research and advancements with the global scientific community.

🔬Research Focus:

Dr. Skiba’s research primarily centers on pharmaceutical technology, with a particular focus on cyclodextrin and drug vectorization. His work involves improving drug delivery systems, studying bio-polymeric materials, and developing innovative pharmaceutical formulations. He has been involved in numerous pharmaceutical research projects since 1990, contributing to the advancement of drug delivery and formulation technologies.

Publication Top Notes:

  • Powder Self-Emulsifying Drug Delivery System for Mitotane: In Vitro and In Vivo Evaluation
  • In vitro dissolution of encapsulated or dispersed vitamin E and cholesterol is correlated with preservation of refrigerated ovine sperm
  • Exploring the Therapeutic Potential of Algerian Propolis: GC/MS Profiling, Protective Inclusion Complex, and In Silico Evaluation Against SARS‐CoV‐2 Main Proteases
  • Development of a Novel Cyclodextrin–Chitosan Polymer for an Efficient Removal of Pharmaceutical Contaminants in Aqueous Solution

 

 

Dr. Angela Fabiano | Pharmaceutics Awards | Best Researcher Award

Dr. Angela Fabiano | Pharmaceutics Awards | Best Researcher Award

Dr. Angela Fabiano,University of Pisa,Italy

Angela Fabiano is a senior researcher at the University of Pisa, Department of Pharmacy, specializing in drug delivery systems. She earned her Ph.D. in Science of Drugs and Bioactive Substances in 2016, with a focus on innovative pharmaceutical systems based on chitosan and its derivatives. Her research involves the synthesis, purification, and characterization of chitosan derivatives to enhance solubility and pharmaceutical applications, including nanosystems and hydrogels for drug delivery via ocular and oral routes. In 2020, she achieved the scientific qualification for associate professor and has authored over 30 publications, with around 800 citations.

Professional Profile:

Orcid

Scopus

Suitability for Best Researcher Award:

Angela Fabiano’s innovative research in drug delivery systems, significant academic contributions, and recognized scientific qualifications make her an outstanding candidate for the Best Researcher Award. Her work directly impacts the development of novel pharmaceutical systems, positioning her as a leader in her field.

🎓Education:

Angela Fabiano earned her Ph.D. in Science of Drugs and Bioactive Substances from the University of Pisa in 2016. Her doctoral thesis, titled “Innovative Pharmaceutical Systems Based on Chitosan and Its Derivatives,” focused on developing novel pharmaceutical systems using chitosan and its derivatives. Her research explored the synthesis, purification, and characterization of these derivatives to improve solubility and expand their pharmaceutical applications, particularly in the creation of advanced drug delivery systems. This work laid the foundation for her continued contributions to drug delivery research.

🏢Work Experience:

Angela Fabiano is currently a Senior Researcher at the Department of Pharmacy, University of Pisa. Her research focuses on drug delivery systems, specifically the synthesis, purification, and characterization of chitosan derivatives. She is dedicated to advancing the development of nanosystems and hydrogels for drug delivery through various routes, including ocular and oral. Her work aims to enhance the effectiveness and versatility of pharmaceutical applications, contributing significantly to the field of drug delivery.

🏅Awards & Achievements:

Angela Fabiano is currently a Senior Researcher at the Department of Pharmacy, University of Pisa. Her research focuses on drug delivery systems, including the synthesis, purification, and characterization of chitosan derivatives. She is also involved in the development of advanced nanosystems and hydrogels for drug delivery through ocular and oral routes. In 2020, she achieved scientific qualification for the role of Associate Professor at the University of Pisa. She has authored over 30 publications in journals with medium to high impact factors, and her work has been cited approximately 800 times, underscoring her significant contributions to the field.

Publication Top Notes:

  • Title: Cross-Linked Thiolated Hydroxypropyl-β-Cyclodextrin for Pulmonary Drug Delivery
  • Title: Olive Leaf Extracts from Three Italian Olive Cultivars Exposed to Drought Stress Differentially Protect Cells against Oxidative Stress
  • Title: Betaine- and L-Carnitine-Based Ionic Liquids as Solubilising and Stabilising Agents for the Formulation of Antimicrobial Eye Drops Containing Diacerein
  • Title: Bergamot Essential Oil: A Method for Introducing It in Solid Dosage Forms
  • Title: Thiolated Hydroxypropyl-β-Cyclodextrin: A Potential Multifunctional Excipient for Ocular Drug Delivery